Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce - 2Vote In favor of Your #1 Method for diminishing Pressure
- 3Malaysian broadcaster rejects altered graphic about electricity rate hike
- 4The pinch at the pump continues on
- 5Prehistoric wolf’s gut frozen in time reveals an ice age giant
- Report in relation to renaming Herzog Park set to be withdrawn
- Eurovision Song Contest changes voting rules after controversial allegations against Israel
- Humpback whale stranded on Germany's Baltic coast frees itself
- Key Little Things That Advantage Old People
- People are getting their news from AI – and it’s altering their views
- Step by step instructions to Advance the Eco-friendliness of Your Kona SUV
- Former 'Bachelorette' welcomes 1st baby via emergency c-section
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- IDF says up to 90% of Iran’s weapons industry could be hit within days
